首页|期刊导航|Pharmacoeconomics and Policy|Cost-effectiveness analysis of bevifibatide for patients with acute coronary syndrome undergoing percutaneous coronary intervention in China

Cost-effectiveness analysis of bevifibatide for patients with acute coronary syndrome undergoing percutaneous coronary intervention in ChinaOA

中文摘要

This study evaluated the cost‑effectiveness of bevifibatide versus eptifibatide for acute coronary syndrome(ACS)patients undergoing percutaneous coronary intervention(PCI)in China.A 30‑day decision tree and 15‑year Markov model simulated outcomes using matching‑adjusted indirect comparison data.Base‑case analysis used the current listed price of bevifibatide(¥1290/vial).Costs and quality‑adjusted life‑years(QALYs)were evaluated against willingness‑to‑pay(WTP)thresholds based on China''s per capita gross domestic product(GDP).Base‑case results showed bevifibatide added¥12,909.24 and 0.0595 QALYs,yielding an incremental cost‑effectiveness ratio(ICER)of¥216,899/QALY.This significantly exceeds the¥76,599 WTP threshold(0.8 times GDP),indicating it is not cost‑effective.Lifetime analysis confirmed these results(ICER:¥159,541/QALY).Threshold analysis indicated a price reduction to approximately¥595/vial is required to achieve cost‑effectiveness.In conclusion,bevifibatide is not cost‑effective for ACS patients undergoing PCI in China at its current price.A substantial price reduction is necessary to align cost with clinical value,providing an evidence‑based threshold for future reimbursement negotiations.

Kaijie Yao;Yun Bao;Ying Chen;Yan Zhong;Mengxia Yan;Wen Li;Bin Wu

Department of Pharmacy,Shanghai Chest Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai,200030,ChinaWest China School of Pharmacy,Sichuan University,Chengdu,610041,China Institute of Clinical Research and Evidence Based Medicine,Gansu Provincial Hospital,Lanzhou,730000,ChinaDepartment of Pharmacy,Shanghai Chest Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai,200030,ChinaPolicy Research Office,Health Management Centre,China Human Health Science and Technology Promotion Association,Beijing,100010,ChinaDepartment of Pharmacy,Ningbo Hangzhou Bay Hospital,Ningbo,Zhejiang,315336,ChinaDepartment of Pharmacy,Ren Ji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai,200127,ChinaDepartment of Pharmacy,Shanghai Chest Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai,200030,China

医药卫生

Cost‑effectiveness analysisBevifibatideEptifibatideAcute coronary syndromePercutaneous coronary intervention

《Pharmacoeconomics and Policy》 2026 (1)

P.46-53,8

10.1016/j.pharp.2026.03.006

评论